Uterine Neoplasms Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lowerlevel evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lowerlevel evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.OverviewAdenocarcinoma of the endometrium is the most common malignancy in the female genital tract in the United States. An estimated 40,100 new diagnoses of uterine cancer and 7470 deaths from this disease will occur in 2008.1 Uterine sarcomas are uncommon and account for approximately 1 in 12 of all uterine cancers.2 These guidelines describe epithelial carcinomas and uterine sarcomas; each of these major categories contains specific histologic groups that require different management (see page 500).By definition, these guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. Exceptions to the rule were discussed among panel members during the process of developing these guidelines.For patients with suspected uterine neoplasms, initial preoperative evaluation includes a history and physical examination, endometrial biopsy, chest radiograph, a CBC,...

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008;58:7196.

  • 2

    Olah K, Gee H, Blunt S. Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer 1991;27:10951099.

  • 3

    Ueda SM, Kapp DS, Cheung MK. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008;198:218.e16.

    • Search Google Scholar
    • Export Citation
  • 4

    Duk JM, Aalders JG, Fleuren GJ. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986;155:10971102.

  • 5

    Duk JM, Aalders JG, Fleuren GJ. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet Gynecol 1989;73:661668.

    • Search Google Scholar
    • Export Citation
  • 6

    Patsner B, Orr JW Jr, Mann WJ Jr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol 1990;162:427429.

    • Search Google Scholar
    • Export Citation
  • 7

    Rose PG, Sommers RM, Reale FR. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol 1994;84:1216.

    • Search Google Scholar
    • Export Citation
  • 8

    Price FV, Chambers SK, Carcangiu ML. CA 125 may not reflect disease status in patients with uterine serous carcinoma. Cancer 1998;82:17201725.

    • Search Google Scholar
    • Export Citation
  • 9

    Gimpelson RJ, Rappold HO. A comparative study between panoramic hysterectomy with directed biopsies and dilatation and curettage: a review of 276 cases. Am J Obstet Gynecol 1998;158:489492.

    • Search Google Scholar
    • Export Citation
  • 10

    Boronow RC, Morrow CP, Creasman WT. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 1984;63:825832.

    • Search Google Scholar
    • Export Citation
  • 11

    Cowles TA, Magrina JF, Masterson BJ. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol 1985;66:413416.

    • Search Google Scholar
    • Export Citation
  • 12

    Creasman WT, Morrow CP, Bundy BN. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer 1987;60:20352041.

    • Search Google Scholar
    • Export Citation
  • 13

    Benedet JL, Bender H, Jones H III. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209262.

    • Search Google Scholar
    • Export Citation
  • 14

    American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005;106:413425.

    • Search Google Scholar
    • Export Citation
  • 15

    Mariani A, Dowdy SC, Cliby WA. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008;109:1118.

    • Search Google Scholar
    • Export Citation
  • 16

    Chan JK, Wu H, Cheung MK. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol 2007;106:282288.

  • 17

    Chan JK, Kapp DS. Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol 2007;8:831841.

  • 18

    ASTEC study group Kitchener H, Swart AM. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125136.

    • Search Google Scholar
    • Export Citation
  • 19

    Benedetti Panici P, Basile S, Maneschi F. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:17071716.

    • Search Google Scholar
    • Export Citation
  • 20

    Creasman WT, Odicino F, Maisonneuve P. Carcinoma of the corpus uteri. FIGO 6th annual report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S105143.

    • Search Google Scholar
    • Export Citation
  • 21

    Fishman DA, Roberts KB, Chambers JT. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol 1996;61:189196.

    • Search Google Scholar
    • Export Citation
  • 22

    Daniel AG, Peters WA III. Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Gynecol Oncol 1988;71:612614.

    • Search Google Scholar
    • Export Citation
  • 23

    Goff BA, Rice LW. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 1990;38:4648.

  • 24

    Kilgore LC, Partridge EE, Alvarez RD. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56:2933.

    • Search Google Scholar
    • Export Citation
  • 25

    Havrilesky LJ, Cragun JM, Calingaert B. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol 2005;99:689695.

    • Search Google Scholar
    • Export Citation
  • 26

    Creutzberg CL, van Putten WL, Koper PC. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:14041411.

    • Search Google Scholar
    • Export Citation
  • 27

    Aalders J, Abeler V, Kolstad P. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419427.

    • Search Google Scholar
    • Export Citation
  • 28

    Keys HM, Roberts JA, Brunetto VL. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744751.

    • Search Google Scholar
    • Export Citation
  • 29

    Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 2004;22:12341241.

    • Search Google Scholar
    • Export Citation
  • 30

    Scholten AN, van Putten WL, Beerman H. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834838.

    • Search Google Scholar
    • Export Citation
  • 31

    Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2005;62:111117.

    • Search Google Scholar
    • Export Citation
  • 32

    Nout RA, Putter H, Jürgenliemk-Schulz IM. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: results of the randomized PORTEC-2 trial [abstract]. J Clin Oncol 2008;26:Abstract LBA5503.

    • Search Google Scholar
    • Export Citation
  • 33

    ASTEC/EN.5 Study Group Blake P, Swart AM. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373:137146.

    • Search Google Scholar
    • Export Citation
  • 34

    Lee CM, Szabo A, Shrieve DC. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 2006;295:389397.

    • Search Google Scholar
    • Export Citation
  • 35

    Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007;114:13131320.

    • Search Google Scholar
    • Export Citation
  • 36

    Kong A, Johnson N, Cornes P. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2007;CD003916.

  • 37

    Koh WJ, Tran AB, Douglas JG. Radiation therapy in endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2001;15:417432.

  • 38

    Hogberg T, Rosenberg P, Kristensen G. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) [abstract]. J Clin Oncol 2007;25:Abstract 5503.

    • Search Google Scholar
    • Export Citation
  • 39

    Morrow CP, Bundy BN, Kurman RJ. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:5565.

    • Search Google Scholar
    • Export Citation
  • 40

    Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 1992;46:145149.

    • Search Google Scholar
    • Export Citation
  • 41

    Owen Mumford. Best Practice Guidelines on the Use of Vaginal Dilators in Women Receiving Pelvic radiotherapy. Available at: http://www.owenmumford.com/en/download.asp?id=59. Accessed March 25, 2009.

    • Search Google Scholar
    • Export Citation
  • 42

    Walker JL, Piedmonte M, Spirtos N. Surgical staging of uterine cancer: randomized phase III trial of laparoscopy vs laparotomy—a Gynecologic Oncology Group study (GOG): preliminary results [Abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 5010.

    • Search Google Scholar
    • Export Citation
  • 43

    Malur S, Possover M, Michels W, Schneider A. Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer—a prospective randomized trial. Gynecol Oncol 2001;80:239244.

    • Search Google Scholar
    • Export Citation
  • 44

    Obermair A, Manolitsas TP, Leung Y. Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival. Gynecol Oncol 2004;92:789793.

    • Search Google Scholar
    • Export Citation
  • 45

    Boggess JF, Gehrig PA, Cantrell L. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol 2008;199:360.e19.

    • Search Google Scholar
    • Export Citation
  • 46

    Bandera CA, Magrina JF. Robotic surgery in gynecologic oncology. Curr Opin Obstet Gynecol 2009;21:2530.

  • 47

    Chadha M, Nanavati PJ, Liu P. Patterns of failure in endometrial carcinoma stage IB, grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol 1999;75:103107.

    • Search Google Scholar
    • Export Citation
  • 48

    Kong A, Powell M, Blake P. The role of postoperative radiotherapy in carcinoma of the endometrium. Clin Oncol (R Coll Radiol) 2008;20:457462.

    • Search Google Scholar
    • Export Citation
  • 49

    Solhjem MC, Petersen IA, Haddock MG. Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer. Int J Radiat Oncol Biol Phys 2005;62:13791384.

    • Search Google Scholar
    • Export Citation
  • 50

    Chi DS, Barakat RR, Palayekar MJ. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer 2008;18:269273.

    • Search Google Scholar
    • Export Citation
  • 51

    Gretz HF III, Economos K, Husain A. The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol 1996;61:409415.

    • Search Google Scholar
    • Export Citation
  • 52

    Ben-Shachar I, Pavelka J, Cohn DE. Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol 2005;105:487493.

    • Search Google Scholar
    • Export Citation
  • 53

    Greven KM, Lanciano RM, Corn B. Pathologic stage III endometrial carcinoma-prognostic factors and patterns of recurrence. Cancer 1993;71:36973702.

    • Search Google Scholar
    • Export Citation
  • 54

    Susumu N, Sagae S, Udagawa Y. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226233.

    • Search Google Scholar
    • Export Citation
  • 55

    Hogberg T. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials. Clin Oncol (R Coll Radiol) 2008;20:463469.

  • 56

    Fleming G. Adjuvant therapy for high-risk adenocarcinoma of the uterus. ASCO Educational Book 2008:230233.

  • 57

    Gibbons S, Martinez A, Schray M. Adjuvant whole abdominopelvic irradiation for high-risk endometrial carcinoma. Int J Radiat Oncol Biol Phys 1991;21:10191025.

    • Search Google Scholar
    • Export Citation
  • 58

    Greer BE, Hamberger AD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation. Gynecol Oncol 1983;16:365373.

    • Search Google Scholar
    • Export Citation
  • 59

    Randall ME, Filiaci VL, Muss H. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:3644.

    • Search Google Scholar
    • Export Citation
  • 60

    Homesley HD, Filiaci V, Gibbons SK. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study [abstract]. 39th Annual Meeting of the Society of Gynecologic Oncologists; Tampa, FL; March 9, 2008. Abstract #1. Gynecol Oncol 2008;108:S2.

    • Search Google Scholar
    • Export Citation
  • 61

    Smith DC, Prentice R, Thompson DJ. Association of exogenous estrogen and endometrial cancer. N Engl J Med 1975;293:11641167.

  • 62

    Ziel HK, Finkle WD. Increased incidence of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:11671170.

  • 63

    Creasman WT, Henderson D, Hinshaw W. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326330.

    • Search Google Scholar
    • Export Citation
  • 64

    Lee RB, Burke TW, Parke RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189191.

    • Search Google Scholar
    • Export Citation
  • 65

    Chapman JA, DiSaia PJ, Osann K. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:11951200.

    • Search Google Scholar
    • Export Citation
  • 66

    Gotlieb WH, Beiner ME, Shalmon B. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 2003;102:718725.

    • Search Google Scholar
    • Export Citation
  • 67

    Ramirez PT, Frumovitz M, Bodurka DC. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95:133138.

    • Search Google Scholar
    • Export Citation
  • 68

    Podczaski E, Kaminski P, Gurski K. Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery. Gynecol Oncol 1992;47:323327.

    • Search Google Scholar
    • Export Citation
  • 69

    Shumsky AG, Stuart GC, Brasher PM. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 1994;55:229233.

    • Search Google Scholar
    • Export Citation
  • 70

    Berchuck A, Anspach C, Evans AC. Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. Gynecol Oncol 1995;59:2022.

    • Search Google Scholar
    • Export Citation
  • 71

    Reddoch JM, Burke TW, Morris M. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol 1995;59:221225.

    • Search Google Scholar
    • Export Citation
  • 72

    Greer BE, Goff BA, Koh WJ. Endometrial carcinoma. In: Johnson FE, Virgo KS, eds. Cancer Patient Follow-up. St. Louis: Mosby; 1997:357377.

  • 73

    Barakat RR, Goldman NA, Patel DA. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 1999;75:99102.

  • 74

    Dowdy SC, Mariani A, Cliby WA. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol 2006;101:280286.

    • Search Google Scholar
    • Export Citation
  • 75

    Tran PT, Su Z, Hara W. Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys 2007;69:504511.

    • Search Google Scholar
    • Export Citation
  • 76

    Poulsen MG, Roberts SJ. The salvage of recurrent endometrial carcinoma in the vagina and pelvis. Int J Radiat Oncol Biol Phys 1988;15:809813.

    • Search Google Scholar
    • Export Citation
  • 77

    Kauppila A. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol 1989;28:561566.

    • Search Google Scholar
    • Export Citation
  • 78

    Thigpen JT, Brady MF, Alvarez RD. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17:17361744.

    • Search Google Scholar
    • Export Citation
  • 79

    Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecol Oncol 1989;32:13.

  • 80

    Thigpen T, Brady MF, Homesley HD. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001;19:364367.

    • Search Google Scholar
    • Export Citation
  • 81

    Burke TW, Walker CL. Arzoxifene as therapy for endometrial cancer. Gynecol Oncol 2003;90(2 Pt 2):S4046.

  • 82

    Quinn MA. Hormonal treatment of endometrial cancer. Hematol Oncol Clin North Am 1999;13:163187.

  • 83

    Fleming GF, Brunetto VL, Cella D. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004;22:21592166.

    • Search Google Scholar
    • Export Citation
  • 84

    Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol 1994;21:107113.

  • 85

    Reddy SP, Kudelka AP, Gonzalez de Leon C. Tumors of the uterine corpus. In: Pazdur R, ed. Medical Oncology: A Comprehensive Review. Huntington: PRR; 1996:407416.

    • Search Google Scholar
    • Export Citation
  • 86

    Sovak MA, Dupont J, Hensley ML. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer 2007;17:197203.

    • Search Google Scholar
    • Export Citation
  • 87

    Secord AA, Havrilesky LJ, Carney ME. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol 2007;12:3136.

    • Search Google Scholar
    • Export Citation
  • 88

    Goff BA, Kato D, Schmidt RA. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994,53:264268.

  • 89

    Hendrickson MR, Longacre TA, Kempson RL. Uterine papillary serous carcinoma revisited. Gynecol Oncol 1994;54:261263.

  • 90

    McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687690.

    • Search Google Scholar
    • Export Citation
  • 91

    Kelly MG, O’Malley DM, Hui P. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005;98:353359.

    • Search Google Scholar
    • Export Citation
  • 92

    Thomas MB, Mariani A, Cliby WA. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol 2007;107:186189.

    • Search Google Scholar
    • Export Citation
  • 93

    Goldberg H, Miller RC, Abdah-Bortnyak R. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol 2008;108:298305.

    • Search Google Scholar
    • Export Citation
  • 94

    Hamilton CA, Cheung MK, Osann K. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol 2006;103:679683.

    • Search Google Scholar
    • Export Citation
  • 95

    Grice J, Ek M, Greer BE. Uterine papillary serous carcinoma (UPSC): evaluation of long-term survival in 36 surgically staged patients. Gynecol Oncol 1998;69:6973.

    • Search Google Scholar
    • Export Citation
  • 96

    Havrilesky LJ, Secord AA, Bae-Jump V. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 2007;105:677682.

  • 97

    Mehta N, Yamada SD, Rotmensch J, Mundt AJ. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003;57:10041009.

    • Search Google Scholar
    • Export Citation
  • 98

    Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003;55:12721276.

    • Search Google Scholar
    • Export Citation
  • 99

    Sood BM, Jones J, Gupta S. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys 2003;57:208216.

    • Search Google Scholar
    • Export Citation
  • 100

    Wolfson AH, Brady MF, Rocereto T. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177185.

    • Search Google Scholar
    • Export Citation
  • 101

    Homesley HD, Filiaci V, Markman M. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:526531.

    • Search Google Scholar
    • Export Citation
  • 102

    Sutton G, Kauderer J, Carson LF. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:630634.

    • Search Google Scholar
    • Export Citation
  • 103

    Reed NS, Mangioni C, Malmström H. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer 2008;44:808818.

    • Search Google Scholar
    • Export Citation
  • 104

    Callister M, Ramondetta LM, Jhingran A. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004;58:786796.

    • Search Google Scholar
    • Export Citation
  • 105

    Chi D, Mychalczak B, Saigo P. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997;65:493498.

    • Search Google Scholar
    • Export Citation
  • 106

    Knocke T, Weitmann H, Kucera H. Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri. Gynecol Oncol 1999;73:389395.

    • Search Google Scholar
    • Export Citation
  • 107

    Larson B, Silfversward C, Nilsson B. Mixed mullerian tumours of the uterus—prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol 1990;17:123132.

    • Search Google Scholar
    • Export Citation
  • 108

    Gerszten K, Faul C, Kounelis S. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998;68:813.

  • 109

    Dusenbery KE, Potish RA, Argenta PA, Judson PL. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol 2005;28:295300.

    • Search Google Scholar
    • Export Citation
  • 110

    Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 2008;111:8288.

    • Search Google Scholar
    • Export Citation
  • 111

    Wolfson AH, Brady MF, Rocereto T. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177185.

    • Search Google Scholar
    • Export Citation
  • 112

    Pink D, Lindner T, Mrozek A. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 2006;101:464469.

    • Search Google Scholar
    • Export Citation
  • 113

    Mansi J, Ramachandra S, Wiltshaw E. Endometrial stromal sarcomas. Gynecol Oncol 1990;36:113118.

  • 114

    Berchuck A, Rubin S, Hoskins W. Treatment of endometrial stromal tumors. Gynecol Oncol 1990;36:6065.

  • 115

    Weitmann H, Knocke T, Kucera H. Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys 2001;49:739748.

    • Search Google Scholar
    • Export Citation
  • 116

    Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med 2007;357:22772284.

  • 117

    Zivanovic O, Iasonos A, Leitao MM. Stage-specific survival of patients with uterine leiomyosarcoma: a comparison of FIGO and AJCC staging system [abstract]. J Clin Oncol 2008;26:Abstract 5554.

    • Search Google Scholar
    • Export Citation
  • 118

    Giuntoli RN, Metzinger D, DiMarco C. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003;89:460469.

    • Search Google Scholar
    • Export Citation
  • 119

    Dusenbery KE, Potish RA, Judson P. Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. Gynecol Oncol 2004;94:191196.

    • Search Google Scholar
    • Export Citation
  • 120

    Sarcoma Meta-analysis Collaboration (SMAC). Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev 2000;CD001419.

    • Search Google Scholar
    • Export Citation
  • 121

    Hensley ML, Maki R, Venkatraman E. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:28242831.

    • Search Google Scholar
    • Export Citation
  • 122

    Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008;109:329334.

    • Search Google Scholar
    • Export Citation
  • 123

    Look KY, Sandler A, Blessing JA. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol 2004;92:644647.

    • Search Google Scholar
    • Export Citation
  • 124

    Judson I, Radford JA, Harris M. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870877.

    • Search Google Scholar
    • Export Citation
  • 125

    Sutton G, Blessing J, Hanjani P. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:749752.

    • Search Google Scholar
    • Export Citation
  • 126

    Gallup DG, Blessing JA, Andersen W. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2003;89:4851.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1247 809 72
PDF Downloads 618 478 34
EPUB Downloads 0 0 0